CAJ | 학술논문

目的评价晚期胰腺癌经动脉化疗或栓塞的临床效果。方法 36例胰腺癌患者分为两组，18例行动脉化疗或栓塞(介入治疗)，另18例行全身化疗。结果介入治疗组临床受益反应有效率为55.6%(10/18)，全身化疗组为16.7%(3/18)(P<0.05)，介入治疗组和全身化疗组6个月、1年生存率和中位生存期分别为35%、11%、4.4个月和30%、8%、4.1个月(P>0.05)。结论胰腺癌的动脉化疗虽未能提高远期生存率，但能提高临床受益反应。
목적평개만기이선암경동맥화료혹전새적림상효과。방법 36례이선암환자분위량조，18례행동맥화료혹전새(개입치료)，령18례행전신화료。결과개입치료조림상수익반응유효솔위55.6%(10/18)，전신화료조위16.7%(3/18)(P<0.05)，개입치료조화전신화료조6개월、1년생존솔화중위생존기분별위35%、11%、4.4개월화30%、8%、4.1개월(P>0.05)。결론이선암적동맥화료수미능제고원기생존솔，단능제고림상수익반응。
Objective　To evaluate the clinical efficacy of transcatheter arterial infusion (TAI) or transcatheter arterial chemoembolization (TACE) in the treatment of advanced pancreatic cancer. Methods　36 cases of advanced pancreatic cancer were divided into two groups, 18 cases were treated with TAI or TACE(group A), other 18 cases were treated with systemic chemotherapy (group B). Results　The clinical benefit response rate of the group A was 55.6%(10/18) and that of the group B was 16.7%(3/18), respectively(P<0.05). The 6-month, 1-year survival rates and median survival of group A were 35%, 11%, and 4.4 month, respectively; in the contrary, those of group B were 30%, 8%, 4.1 month, respectively (P>0.05). Conclusions　In the transcatheter arterial infusion group, no survival advantage could be demonstrated when compared with the controls, but TAI could effectively increase clinical benefit response and improve the quality of life of advanced pancreatic cancer.